BackgroundPhotoacoustic imaging (PA) with high spatial resolution has great potential as desired monitoring means in the high intensity focused ultrasound (HIFU) surgery of tumor. However, its penetration depth in the tissue does not meet the clinical needs. Nanomedicine provides a new opportunity for PA imaging to guide HIFU surgery. Our studies found that hypoxic heterogeneity of tumor was effectively reversed by HIFU.
MethodsHerein, speci c metal-organic framework nanosystem, constructed by coordination of banoxantrone (AQ4N) and Mn 2+ , is designed based on HIFU to reverse hypoxic heterogeneity of tumor.
ResultsIt could provide exogenous light-absorbing substances, thus improves the penetrability of PA imaging signal through the deep tissue and achieves clearer PA imaging for guiding HIFU surgery. In turn, AQ4N, in the hypoxic homogenous environment of tumor provided by HIFU, is activated sequentially to speci cally treat the residual hypoxic tumor cells.
ConclusionsThis strategy addresses the dissatisfaction of PA imaging-guided HIFU therapy and is promising for translation into a clinical combination regimen.
Background
Photoacoustic imaging (PA) with high spatial resolution has great potential as desired monitoring means in the high intensity focused ultrasound (HIFU) surgery of tumor. However, its penetration depth in the tissue does not meet the clinical needs. Nanomedicine provides a new opportunity for PA imaging to guide HIFU surgery. Our studies found that hypoxic heterogeneity of tumor was effectively reversed by HIFU.
Methods
Herein, specific metal-organic framework nanosystem, constructed by coordination of banoxantrone (AQ4N) and Mn2+, is designed based on HIFU to reverse hypoxic heterogeneity of tumor.
Results
It could provide exogenous light-absorbing substances, thus improves the penetrability of PA imaging signal through the deep tissue and achieves clearer PA imaging for guiding HIFU surgery. In turn, AQ4N, in the hypoxic homogenous environment of tumor provided by HIFU, is activated sequentially to specifically treat the residual hypoxic tumor cells.
Conclusions
This strategy addresses the dissatisfaction of PA imaging-guided HIFU therapy and is promising for translation into a clinical combination regimen.
AbstractObjective
To retrospectively evaluate the oncologic and obstetric outcomes of fertility-sparing surgery (FSS) for borderline ovarian tumors(BOT).
Methods
132 patients with borderline ovarian tumors were divided into the incompletely staging surgery (ISS) group and the completely staging surgery (CSS) group. The overall survival and disease-free survival curves were determined using the Kaplan–Meier method. The Cox proportional hazards method was used to assess the association between the variables and live birth and multivariate analysis to identify the independent associations.
Results
Chi-square and Kaplan-Meier analyses showed no significant differences in overall survival between the two groups (p = 1.000 and p = 0.716, respectively). The CSS group had fewer relapses and longer disease-free survival than ISS (p = 0.003). There was no statistical difference in live birth rate between two groups (crude odds ratio = 0.885, 95%CI 0.411–1.903, p = 0.755; adjusted odds ratio = 0.848, 95%CI 0.366–1.963, p = 0.700). Age was the only independent risk factor for live birth (adjusted odds ratio = 0.902, 95%CI 0.823–0.988, p = 0.027). Mean live birth intervals after FSS was 31.86 ± 19.325 months.
Conclusions
CSS significantly increased the disease-free survival time of BOT and reduced the relapse risk. However, CSS had a slightly negative and statistically insignificant association with live birth.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.